Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Jasper Therapeutics Q2 EPS $(0.29)

Jasper Therapeutics Q2 EPS $(0.29)

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.29) per share.

byMichael Horton

August 12, 2022

1 minute read

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.29) per share.

Why Xponential Fitness (XPOF) Shares Are Falling Tuesday

By Erica Kollmann

June 27, 11:55 AM

Xponential Fitness, Inc. (NASDAQ: XPOF) shares are trading lower on Tuesday after Fuzzy Panda Research issued a short report on the stock. What To Know:

XPOF

Republicans See Advantage In Early Battle Between Biden And Kennedy Jr: The Hill

By Benzinga Newsbot

June 28, 7:17 AM

Republicans are viewing Robert F. Kennedy Jr.‘s Democratic primary challenge as a potential advantage in their efforts against President Biden, The Hill reports.

BTC

What Does Imperial Oil’s Debt Look Like?

By Benzinga Insights

July 6, 9:15 AM

Shares of Imperial Oil Inc. (AMEX:IMO) fell by 6.34% in the past three months. When understanding a companies…

IMO

Indaptus Therapeutics Doses First Patient In Second Cohort Of Single Dose Ranging Study Of Decoy20

By Benzinga Newsdesk

September 19, 8:04 AM

Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company") announces dosing of the first patient in the second cohort of patients to receive a single dose of Decoy20 in the INDP-D101 trial. This cohort dose

INDP

Jasper Therapeutics Q2 EPS $(0.29)

Related Posts

Why Xponential Fitness (XPOF) Shares Are Falling Tuesday

Republicans See Advantage In Early Battle Between Biden And Kennedy Jr: The Hill

What Does Imperial Oil’s Debt Look Like?

Indaptus Therapeutics Doses First Patient In Second Cohort Of Single Dose Ranging Study Of Decoy20